Clinical trial · Observational
HPV Vaccine in Postpartum Women
Increasing Human Papillomavirus Vaccination in Postpartum Women at Penn State Hershey Medical Center
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Revising protocol.
Summary
Brief summary (as posted)
The purpose of this study is to determine the acceptability of HPV vaccination in postpartum women in Central Pennsylvania. Participants will be recruited while inpatient in the postpartum unit. Participants will complete a survey asking about knowledge, attitudes, and beliefs around vaccination, including HPV vaccination, as well as breastfeeding intentions. After survey completion, the participant will have the option to receive the HPV vaccine, Gardasil 9, prior to discharge from the hospital. All participants will then be contacted 1- week later for the follow-up survey.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HPV Infection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HPV 9-valent Vaccine, Recombinant | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Vaccine Accepting
- description
- This group will receive the HPV vaccine in the inpatient postpartum period prior to discharge from the hospital.
- interventionNames
- Biological: HPV 9-valent Vaccine, Recombinant
- label
- Vaccine Rejecting
- description
- This group will not receive the HPV vaccine in the inpatient postpartum period prior to discharge from the hospital.
Primary outcomes (3)
- measure
- Prevalence of postpartum women who agree to HPV vaccination
- timeFrame
- Day 1
- description
- Percentage of women who accept HPV vaccination when offered in the inpatient postpartum setting
- measure
- Perception of HPV vaccination
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 26 Years
Show eligibility criteria text
Inclusion Criteria: 1. Women postpartum with a live birth at Penn State Hershey Medical Center (PSHMC), either vaginal or cesarean delivery. 2. Women aged 18-26 (inclusive) years 3. Women who are on a Floor Status level of care. 4. Women who have completed 0 or 1 doses of the HPV vaccine STUDY00013831 Approval: 5/8/2020 Page 6 of 24 (V.01/21/2019) 5. Fluent in written and spoken English and other languages in which the Human Subjects Protection Office (HSPO) Consent Short From is available (French, Italian, Russian, Spanish, Vietnamese, Hindi, Chinese and Nepali) Exclusion Criteria: 1. Women who have completed 2 or 3 doses of the HPV vaccine 2. Hypersensitivity, including severe allergic reactions to yeast (a vaccine component), or after a previous dose of GARDASIL 9 or GARDASIL®. 3. Allergic reaction to amorphous aluminum hydroxyphosphate sulfate or polysorbate 80 4. Women being actively treated for cancer. 5. Have a fever over 100.4 degrees Fahrenheit (38.0 degrees Celsius) 6. Women who are at an ICU level of Care 7. Women who are on a Labor and Delivery Level of Care 8. Women receiving continuous IV magnesium.
References
Publications (0)
Data not yet available